| WB | 1/100-1/1600 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | T-cell surface glycoprotein CD3 epsilon chain, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T3E |
| Entrez GeneID | 916 |
| WB Predicted band size | 23.1kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | This CD3 Monoclonal antibody is generated from mouses immunized with a KLH conjugated synthetic peptide selected from human CD3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD3抗体的3篇代表性文献(摘要内容为简化概括)：
1. **《Structure and function of the CD3 antigen receptor complex》**
- 作者：Kung, P., et al.
- 摘要：本文阐明了CD3复合体(CD3γ、δ、ε、ζ)与T细胞受体(TCR)的相互作用机制，揭示了其在T细胞抗原识别和信号转导中的核心作用。
2. **《CD3 antibodies as unique tools to restore self-tolerance in autoimmunity》**
- 作者：Chatenoud, L., et al.
- 摘要：研究证明抗CD3单克隆抗体(如OKT3)可通过调节T细胞活性，诱导免疫耐受，用于治疗1型糖尿病等自身免疫疾病，减少传统免疫抑制剂的副作用。
3. **《Anti-CD3 antibody promotes tolerance by selectively activating and deleting pathogenic T cells》**
- 作者：Smith, J.A., et al.
- 摘要：实验表明，特定抗CD3抗体可选择性地激活并清除自身反应性T细胞，同时保留保护性免疫应答，为靶向免疫治疗提供新策略。
4. **《CD3 bispecific antibodies in cancer immunotherapy》**
- 作者：Baeuerle, P.A., et al.
- 摘要：探讨双特异性CD3抗体(如BiTE技术)通过桥接T细胞与肿瘤细胞，增强抗肿瘤免疫应答的机制及临床试验进展。
(注：以上文献信息为示例，实际引用需核对原文及发表信息。)
CD3 antibodies target the CD3 complex, a group of cell surface proteins critical for T-cell receptor (TCR) signaling and T-cell activation. Discovered in the early 1980s, CD3 molecules (CD3ε, γ, δ, and ζ chains) associate with the TCR to form the TCR-CD3 complex, essential for antigen recognition and immune response initiation. CD3 antibodies were first developed as murine monoclonal antibodies (e.g., OKT3) and later humanized to reduce immunogenicity.
Functionally, CD3 antibodies modulate T-cell activity through mechanisms like TCR internalization (antigenic modulation) or selective T-cell depletion. Clinically, they are used to suppress T-cell-mediated immune reactions, such as in organ transplant rejection (e.g., muromonab-CD3) or autoimmune diseases. Recent applications include redirecting T-cells against cancer (bispecific antibodies) and preserving beta cells in type 1 diabetes (teplizumab).
Research also explores CD3 antibodies in CAR-T therapies, where they enhance receptor clustering and signaling. Despite therapeutic promise, challenges like cytokine release syndrome and variable efficacy persist. Advances in antibody engineering aim to improve specificity and safety, solidifying CD3 antibodies as pivotal tools in immunology and immunotherapy.
×
